Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Solid Tumors 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Hodgkin Disease 1Burkitt Lymphoma 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

venetoclax 46Azacitidine 35Specimen Handling 34Cytarabine 31Biopsy 23fludarabine 22Cyclophosphamide 18decitabine and cedazuridine drug combination 14Injections 14Daunorubicin 14fludarabine phosphate 12Whole-Body Irradiation 11Busulfan 11Mycophenolic Acid 10Melphalan 10Tacrolimus 9Idarubicin 9CPX-351 9ivosidenib 8Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8Gemtuzumab 7Decitabine 7Cyclosporine 7enasidenib 6X-Rays 6Magnetic Resonance Spectroscopy 6Filgrastim 6gilteritinib 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × pegylated granulocyte colony-stimulating factor × 30 days × Clear all
NCT04195945 2026-05-14

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Fred Hutchinson Cancer Center

Phase 2 Active not recruiting
60 enrolled 19 charts
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡